ARCT - Is It Too Late to Get in on This Millionaire-Maker Stock?
Surprisingly enough, one of the best performing coronavirus vaccine stocks of the year is Arcturus Therapeutics (NASDAQ: ARCT) . If you had invested $10,000 in the San-Diego based biotech last year, that principal would have grown to a stunning $101,000 as of Dec. 4. That kind of return even beats the more than 600% gain on shares of coronavirus vaccine giant Moderna !
As it turns out, Arcturus is also a company that is investigating messenger RNA based coronavirus vaccines. With the stock so high, many who have just heard of the company wonder if now is too late to invest. Today, let's see whether or not shares of this mid-cap biotech can make you rich, and existing investors even richer.
Image Source: Getty Images.
For further details see:
Is It Too Late to Get in on This Millionaire-Maker Stock?